Breaking News

IntelGenx Granted Amended DEL License to Conduct Third-Party Testing

Provides opportunity to address market gap, catering to growing industry demand for reliable and efficient testing services.

IntelGenx Corp., a drug delivery company, has received an amended Drug Establishment License (DEL) from Health Canada, allowing the company to conduct third-party testing. Analytical testing of finished products and intermediates is a significantly underserved market, which IntelGenx has decided to tap into. IntelGenx views this as an attractive opportunity for short-term revenue generation. The amended DEL license could be of particular importance due to IntelGenx’s possession of a con...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters